MediaMedic

Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma

By Mourabit Halima 2024.03.18

Introduction: Transformed follicular lymphoma (tFL) presents a formidable challenge in clinical oncology due to its high tumor mutational burden and therapeutic resistance. While anlotinib has demonstrated efficacy in solid tumors,…

The Role of SHP-1 and SHP-2 in CD8+ T Cell Regulation during Lymphocytic Choriomeningitis Virus Infection: Insights into Stage-Specific Functional Interplay

By Mourabit Halima 2024.03.18

Abstract: Our study delves into the intricate interplay between Src homology region 2 domain-containing phosphatases 1 and 2 (SHP-1 and SHP-2) in orchestrating the functionality of CD8+ T cells during…

Assessing the Impact of Omicron Variant on Allo-HSCT Recipients in China: Insights from a Single-Center Observational Study

By Mourabit Halima 2024.03.17

Introduction: The emergence of the Omicron variant of SARS-CoV-2 has posed significant challenges to global public health systems. Among vulnerable populations, allo-hematopoietic stem cell transplantation (allo-HSCT) recipients represent a particularly…

The Complex Impact of CMV Reactivation Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comprehensive Review

By Qingyuan Liu 2024.03.17

Abstract: Cytomegalovirus (CMV) reactivation presents a formidable challenge for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with implications for overall mortality (OM) and non-relapse mortality (NRM) that are subject…

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

By Yang Xiaoshan 2024.03.17

Abstract: Refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) poses significant therapeutic challenges, particularly in cases where chimeric antigen receptor T-cell (CAR-T) therapy fails. This retrospective study aimed to evaluate the…

Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives

By Mourabit Halima 2024.03.17

Abstract: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has revolutionized the treatment landscape for patients with relapsed or refractory (R/R) B-cell malignancies. However, the emergence of relapse with CD19-negative…

$Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results$

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

By Mourabit Halima 2024.03.17

Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

By Mourabit Halima 2024.03.17

Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…

Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

By Mourabit Halima 2024.03.17

Editor's note: Acute Myeloid Leukemia (AML) characterized by CCAAT-enhancer binding protein alpha (CEBPA) double mutations (CEBPAdm) represents a distinct subtype with varying clinical outcomes. Recent attention has focused on the…

The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

By Mourabit Halima 2024.03.17

Editor's note: Genetic mutations play a pivotal role in shaping the clinical presentation and prognosis of hematological disorders, with CEBPA mutations emerging as significant contributors to disease pathogenesis. This comprehensive…

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Latest Research from Academician Binghe Xu’s Team: Anucleate Red Blood Cells Act as Tumor DNA “Reservoirs,” with Apoptotic Bodies Identified as the Key Couriers

Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

Annual Review Professor Bing Xu: Interpreting New Paradigms and Future Pathways in the Diagnosis and Treatment of Follicular Lymphoma

CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation

Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Anlotinib: A Promising Therapeutic Approach for Transformed Follicular Lymphoma

The Role of SHP-1 and SHP-2 in CD8+ T Cell Regulation during Lymphocytic Choriomeningitis Virus Infection: Insights into Stage-Specific Functional Interplay

Assessing the Impact of Omicron Variant on Allo-HSCT Recipients in China: Insights from a Single-Center Observational Study

The Complex Impact of CMV Reactivation Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comprehensive Review

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Option for Diffuse Large B-Cell Lymphoma Patients After CAR-T Therapy Failure

Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis

Retrospective Analysis of bZIP Region Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia: Implications for Prognosis and Treatment

The Impact of CEBPA Mutations in Hematological Disorders: A Comprehensive Study

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Breast Cancer Chronicle · 2025 Professor Shusen Wang: Advances in Endocrine Therapy for HR+/HER2− Advanced Breast Cancer — Approval of Inavolisib-Based Combinations and New Pathways Opened by the evERA BC Study

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Latest Research from Academician Binghe Xu’s Team: Anucleate Red Blood Cells Act as Tumor DNA “Reservoirs,” with Apoptotic Bodies Identified as the Key Couriers

Welcome to Mediamedic 👋
It’s nice to meet you.

Welcome to Mediamedic 👋It’s nice to meet you.

Welcome to Mediamedic 👋
It’s nice to meet you.